On Friday, the subject expert committee under the Central Drugs Standard Control Organisation will meet to consider the emergency-use authorisation application of Pfizer, Serum Institute of India (SII) and Bharat Biotech’s Covaxin.
from Hindustan Times - india https://ift.tt/2KUTFY5
from Hindustan Times - india https://ift.tt/2KUTFY5